Date: 2011-02-24
Type of information: Development agreement
Compound: controlled release formulation for one of ESBATech’s proprietary biological compounds for ophthalmic applications
Company: OctoPlus (The Netherlands) ESBATech (Alcon-Novartis subsidiary)(Switzerland)
Therapeutic area: Ophtalmological diseases
Type agreement: development
Action mechanism:
Disease: undisclosed ophtalmic application
Details: OctoPlus has signed a contract with ESBATech, to develop a controlled release formulation for one of its proprietary biological compounds for ophthalmic applications. The project includes process development, scale-up and manufacturing for pre-clinical studies. This drug delivery technology evaluation project started in 2009. OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of ESBATech with its drug delivery technology PolyActive®.
Financial terms: Financial details are not disclosed, but the project will make a material contribution to our annual revenues in 2011.
Latest news:
